Barrier-repair prescription moisturizers: Do we really need them? Facts and controversies

Clinics in Dermatology

Volumn 31, Issue 6, 2013, Pages 787-791

  Wolf, Ronni ^a,b   Parish, Lawrence Charles ^c  

^a KAPLAN MEDICAL CENTER   (Israel)

^b HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIECZEMA AGENT; ANTIINFLAMMATORY AGENT; ATOPICLAIR; DERMATOLOGICAL AGENT; ELETONE; EMOLLIENT AGENT; EPICERAM; FLUTICASONE PROPIONATE; HYALURONIC ACID; MIMYX; NON PRESCRIPTION DRUG; PIMECROLIMUS; TOPICAL AGENT; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

ATOPIC DERMATITIS; CYTOKINE RELEASE; DRUG EFFICACY; DRUG RESPONSE; DRY SKIN; ECZEMA; HUMAN; NOTE; PATHOGENESIS; PRESCRIPTION; PRIORITY JOURNAL; SKIN WATER LOSS; TREATMENT OUTCOME;

CERAMIDES; CETOMACROGOL; CHOLESTEROL; DERMATITIS, ATOPIC; DRUG COMBINATIONS; EMOLLIENTS; ENDOCANNABINOIDS; ETHANOLAMINES; FATTY ACIDS; FATTY ALCOHOLS; HUMANS; MINERAL OIL; NONPRESCRIPTION DRUGS; PALMITIC ACIDS; PETROLATUM; PRESCRIPTION DRUGS; SKIN CREAM; WATER LOSS, INSENSIBLE;

EID: 84886036219     PISSN: 0738081X     EISSN: 18791131     Source Type: Journal    
DOI: 10.1016/j.clindermatol.2013.05.018     Document Type: Note

References (18)

1. Elias P.M., Feingold K.R. Does the tail wag the dog? Role of the barrier in the pathogenesis of inflammatory dermatoses and therapeutic implications. Arch Dermatol 2001, 137:1079-1081.
2. Sajic D., Asiniwasis R., Skotnicki-Grant S. A look at epidermal barrier function in atopic dermatitis: physiologic lipid replacement and the role of ceramides. Skin Therapy Lett 2012, 17:6-9.
3. Elias P.M. An Appropriate response to the black-box warning: corrective, barrier repair therapy in atopic dermatitis. Clin Med Dermatol 2009, 2:1-3.
4. Chamlin S.L., Frieden I.J., Fowler A., et al. Ceramide-dominant, barrier-repair lipids improve childhood atopic dermatitis. Arch Dermatol 2001, 137:1110-1112.
5. Chamlin S.L., Kao J., Frieden I.J., et al. Ceramide-dominant barrier repair lipids alleviate childhood atopic dermatitis: changes in barrier function provide a sensitive indicator of disease activity. J Am Acad Dermatol 2002, 47:198-208.
6. Sugarman J.L., Parish L.C. Efficacy of a lipid-based barrier repair formulation in moderate-to-severe pediatric atopic dermatitis. J Drugs Dermatol 2009, 8:1106-1111.
7. Kircik L.H., Del Rosso J.Q., Aversa D. Evaluating clinical use of a ceramide-dominant, physiologic lipid-based topical emulsion for atopic dermatitis. J Clin Aesthet Dermatol 2011, 4:34-40.
8. Kircik L.H., Del Rosso J.Q. Nonsteroidal treatment of atopic dermatitis in pediatric patients with a ceramide-dominant topical emulsion formulated with an optimized ratio of physiological lipids. J Clin Aesthet Dermatol 2011, 4:25-31.
9. Draelos Z.D. A clinical evaluation of the comparable efficacy of hyaluronic acid-based foam and ceramide-containing emulsion cream in the treatment of mild-to-moderate atopic dermatitis. J Cosmet Dermatol 2011, 10:185-188.
10. Abramovits W., Boguniewicz M. A multicenter, randomized, vehicle-controlled clinical study to examine the efficacy and safety of MAS063DP (Atopiclair) in the management of mild to moderate atopic dermatitis in adults. J Drugs Dermatol 2006, 5:236-244.
11. Abramovits W., Hebert A.A., Boguniewicz M., et al. Patient-reported outcomes from a multicenter, randomized, vehicle-controlled clinical study of MAS063DP (Atopiclair) in the management of mild-to-moderate atopic dermatitis in adults. J Dermatolog Treat 2008, 19:327-332.
12. Boguniewicz M., Zeichner J.A., Eichenfield L.F., et al. MAS063DP is effective monotherapy for mild to moderate atopic dermatitis in infants and children: a multicenter, randomized, vehicle-controlled study. J Pediatr 2008, 152:854-859.
13. Patrizi A., Capitanio B., Neri I., et al. A double-blind, randomized, vehicle-controlled clinical study to evaluate the efficacy and safety of MAS063DP (ATOPICLAIR) in the management of atopic dermatitis in paediatric patients. Pediatr Allergy Immunol 2008, 19:619-625.
14. Eberlein B., Eicke C., Reinhardt H.W., Ring J. Adjuvant treatment of atopic eczema: assessment of an emollient containing N-palmitoylethanolamine (ATOPA study). J Eur Acad Dermatol Venereol 2008, 22:73-82.
15. Emer J.J., Frankel A., Sohn A., Lebwohl M. A bilateral comparison study of pimecrolimus cream 1% and a topical medical device cream in the treatment of patients with atopic dermatitis. J Drugs Dermatol 2011, 10:735-743.
16. Draelos Z.D. An evaluation of prescription device moisturizers. J Cosmet Dermatol 2009, 8:40-43.
17. Miller D.W., Koch S.B., Yentzer B.A., et al. An over-the-counter moisturizer is as clinically effective as, and more cost-effective than, prescription barrier creams in the treatment of children with mild-to-moderate atopic dermatitis: a randomized, controlled trial. J Drugs Dermatol 2011, 10:531-537.
18. Ring J., Alomar A., Bieber T., et al. Guidelines for treatment of atopic eczema (atopic dermatitis) part I. J Eur Acad Dermatol Venereol 2012, 26:1045-1060.